Navigation Links
Johnson & Johnson Completes Initial Tender Offer for Mentor Corporation with 92.9% of Shares Tendered
Date:1/17/2009

- Johnson & Johnson Will Commence Subsequent Offering Period

NEW BRUNSWICK, N.J., Jan. 17 /PRNewswire-FirstCall/ -- Johnson & Johnson (NYSE: JNJ) today announced that the initial tender offer, through its wholly owned subsidiary, Maple Merger Sub, Inc., for all outstanding shares of common stock of Mentor Corporation (NYSE: MNT) expired at 5:00 PM (Eastern time) on Jan. 16, 2009, and was not extended.

The depositary for the tender offer has advised Johnson & Johnson that, as of the expiration of the initial tender offer, a total of approximately 31,456,557 shares of Mentor common stock were validly tendered and not withdrawn (including approximately 4,632,228 shares subject to guaranteed delivery procedures), representing approximately 92.9% of the outstanding shares of Mentor common stock. All shares that were validly tendered and not properly withdrawn during the initial offering period have been accepted for payment.

Johnson & Johnson also announced that it will commence through Maple Merger Sub, Inc., a subsequent offering period to acquire all remaining shares of Mentor common stock, which will begin on Tuesday, Jan. 20, 2009 and expire at 12:00 midnight (Eastern time) on Jan. 22, 2009, unless extended. Any shares validly tendered during the subsequent offering period will be immediately accepted for payment, and tendering shareholders will promptly thereafter be paid $31.00 per share, less any required withholding taxes, in cash and without interest, which is the same amount per share that was offered and paid in the initial offering period. The subsequent offering period enables holders of shares of Mentor common stock who did not tender during the initial offering period to participate in the offer and receive the offer price on an expedited basis rather than waiting until the completion of the merger described below. Shares tendered during the subsequent offering period cannot be delivered by the guaranteed delivery procedure and may not be withdrawn. In addition, shares validly tendered during the initial offering period may not be withdrawn during the subsequent offering period.

If, following the expiration of the subsequent offering period, Maple Merger Sub, Inc. owns at least 90% of the shares of Mentor common stock outstanding, the merger will be completed through what is known as a "short-form merger" without a vote or meeting of Mentor's remaining shareholders.

Upon closing, the transaction is expected to have a dilutive impact to Johnson & Johnson's 2009 earnings per share of approximately $.03 - $.05. This amount will be reflected as part of Johnson & Johnson's earnings guidance, which will be provided on Jan. 20, 2009.

About Johnson & Johnson

Caring for the world, one person at a time...inspires and unites the people of Johnson & Johnson. We embrace research and science -- bringing innovative ideas, products and services to advance the health and well-being of people. Our 119,400 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.

Additional Information

This press release is neither an offer to purchase nor a solicitation of an offer to sell shares of Mentor Corporation. Johnson & Johnson and Maple Merger Sub, Inc. have filed a tender offer statement with the Securities and Exchange Commission ("SEC"), and have mailed an offer to purchase, forms of letter of transmittal and related documents to Mentor shareholders. Mentor has filed with the SEC, and has mailed to Mentor shareholders, a solicitation/recommendation statement on Schedule 14D-9. These documents contain important information about the tender offer and shareholders of Mentor are urged to read them carefully.

These documents are available at no charge at the SEC's website at www.sec.gov. The tender offer statement and the related materials may be obtained for free by directing a request by mail to Georgeson Inc., 199 Water Street, New York, New York 10038 or by calling toll-free (800) 213-0475 or (800) 445-1790. In addition, a copy of the offer to purchase, letter of transmittal and certain other related tender offer documents may be obtained free of charge by directing a request to Johnson & Johnson at www.jnj.com, or Johnson & Johnson, One Johnson & Johnson Plaza, New Brunswick, New Jersey 08933, Attn: Corporate Secretary's Office.


'/>"/>
SOURCE Johnson & Johnson
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Johnson & Johnson Announces Satisfaction of Regulatory Clearances Condition for its Proposed Acquisition of Mentor Corporation
2. Former Johnson & Johnson Executive Gives Big Voice to Small Companies
3. Johnson & Johnson to Review Fourth-Quarter and Full-Year 2008 Financial Results
4. Johnson & Johnson Completes Tender Offer for Omrix Biopharmaceuticals, Inc.
5. Johnson & Johnson Announces Receipt of Israeli Antitrust Approval for Acquisition of Omrix
6. YMCA of the USA Expands Healthy Communities Initiatives With $6.8 Million Grant from the Robert Wood Johnson Foundation
7. Johnson Matthey Medical Announces Expansion
8. Robert Wood Johnson Foundation Awards Grants to Nine Communities In Launch of $44 Million National Program to Reverse Childhood Obesity
9. Video: Magic Johnson Foundation and Abbott Call for Greater Prevention, Testing and Treatment on World AIDS Day
10. Johnson & Johnson Begins Tender Offer to Acquire Omrix
11. UC San Diego announces collaboration with Johnson & Johnson Pharmaceutical Research & Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... ... ... More than a third of American adults are considered obese, says the ... increased attention in recent years, as an article published May 18th on ... people are familiar with the basic requirements of maintaining a healthy diet and exercise ...
(Date:5/27/2016)... ... 2016 , ... With over 60 percent of acute stroke survivors being left ... to aid in the rehabilitation process has steadily increased. Ekso Bionics had been working ... due to stroke. , Ekso Bionics has now received clearance from the U.S. Food ...
(Date:5/27/2016)... York, NY (PRWEB) , ... May 27, 2016 ... ... care world, this installment is bolstered by inspiring human interest stories, courtesy of ... the developing trends and tech within the industry, from leading advocates and associations—namely ...
(Date:5/26/2016)... ... ... There are many ways to cook a hot dog, but new research ... their dogs straight off the grill. Of the 90 percent of Americans who say ... a hot dog, far outpacing other cooking methods such as steaming (12 percent), microwaving ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through its Connor Cares ... the Tamika Catchings Legacy Tour that will commemorate the Indiana Fever legend’s ... surfaces in all forms and levels of the game, Connor Sports has committed to ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... study highlights the necessity of health literacy within the technology advancement of diagnostic imaging. According ... , a majority of oncology patients undergo imaging screenings without understanding the nuanced risks ... ... ... Medical Diagnostic Imaging Ampronix ...
(Date:5/27/2016)... , May 27, 2016 ... biopharmaceutical company focused on late-stage drug development, today ... Pharma of pivotal batches required for registration ... Administration (FDA). This follows Kitov,s announcement ... trial successfully met its primary efficacy endpoint. ...
(Date:5/26/2016)... 26, 2016 A key trend ... the emergence of new treatments. Cardax, a development stage ... treatment. The therapy is expected to fulfil large unmet ... is conducting studies to develop new treatments for osteoarthritis. ... genes involved in osteoarthritis are being investigated, and early ...
Breaking Medicine Technology: